Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sintilimab + regorafenib with stereotactic radiotherapy in heavily pretreated pMMR metastatic colorectal cancer
ChiCTR2000031237Phase 2Not yet recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, regorafenib in colorectal cancer (CRC), colorectal adenocarcinoma, sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Planned start May 2020; status: not yet recruiting.
02
Drugs
sintilimabregorafenib
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000031237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031237.